AbbVie, BMS to test Rova-T, Opdivo, and Opdivo + Yervoy combinations; terminated
AbbVie Inc. announced it would test combinations of its Rova-T (rovalpituzumab tesirine) with Bristol-Myers Squibb Co.'s Opdivo (nivolumab) and Opdivo and Yervoy (ipilimumab) combination.
- Gene Therapy, Cell Therapy
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.